- Home
- EIC vs YMAB Comparison
EIC vs YMAB Comparison
Compare EIC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- YMAB
- Stock Information
- Founded
- EIC N/A
- YMAB 2015
- Country
- EIC United States
- YMAB United States
- Employees
- EIC N/A
- YMAB N/A
- Industry
- EIC Finance/Investors Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- YMAB Health Care
- Exchange
- EIC Nasdaq
- YMAB Nasdaq
- Market Cap
- EIC 349.4M
- YMAB 192.4M
- IPO Year
- EIC 2019
- YMAB 2018
- Fundamental
- Price
- EIC $13.78
- YMAB $4.36
- Analyst Decision
- EIC Strong Buy
- YMAB Buy
- Analyst Count
- EIC 1
- YMAB 11
- Target Price
- EIC $17.50
- YMAB $17.55
- AVG Volume (30 Days)
- EIC 204.2K
- YMAB 202.0K
- Earning Date
- EIC 08-05-2025
- YMAB 08-11-2025
- Dividend Yield
- EIC 17.48%
- YMAB N/A
- EPS Growth
- EIC N/A
- YMAB N/A
- EPS
- EIC 0.55
- YMAB N/A
- Revenue
- EIC $51,224,692.00
- YMAB $88,658,000.00
- Revenue This Year
- EIC $42.67
- YMAB N/A
- Revenue Next Year
- EIC $29.16
- YMAB $15.15
- P/E Ratio
- EIC $24.89
- YMAB N/A
- Revenue Growth
- EIC 68.61
- YMAB 4.92
- 52 Week Low
- EIC $12.63
- YMAB $3.55
- 52 Week High
- EIC $16.71
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- EIC 59.85
- YMAB 45.29
- Support Level
- EIC $13.64
- YMAB $4.10
- Resistance Level
- EIC $13.92
- YMAB $4.62
- Average True Range (ATR)
- EIC 0.16
- YMAB 0.29
- MACD
- EIC 0.07
- YMAB -0.04
- Stochastic Oscillator
- EIC 96.83
- YMAB 20.73
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.